EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MEK Inhibitors and Toll-like Receptor Signaling: Implications for Infection and Inflammation

Oliver Planz iD

International Journal of Molecular Sciences · 23.06.2026 · 27 (13) · 5666

DOI: 10.3390/ijms27135666 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.06.2026. Verfasst von Oliver Planz. Beteiligte Einrichtung: Institute of Immunology, University and University Hospital of Tübingen, 72076 Tübingen, Germany. Hauptthemen laut MEDLINE: Toll-Like Receptors, Inflammation, Protein Kinase Inhibitors, Signal Transduction. Die Arbeit nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research, Federal Ministry for Research, Technology and Space.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptors (TLRs) are essential components of the innate immune system that enable host cells to sense microbial and endogenous danger signals and to initiate inflammatory and antimicrobial responses. Activation of TLRs triggers complex intracellular signaling networks that culminate in the induction of pro-inflammatory cytokines, type I interferons, and co-stimulatory molecules. In addition to the well-characterized nuclear factor κB (NF-κB) and interferon regulatory factor (IRF) pathways, mitogen-activated protein kinases (MAPKs) play a critical modulatory role in TLR signaling. MAPK/ERK kinase (MEK) inhibitors were originally developed for the treatment of cancer and are widely used in clinical oncology. Accumulating evidence indicates that pharmacological inhibition of MEK/extracellular signal regulated kinase (ERK) signaling profoundly affects immune cell function and TLR-driven responses. Depending on timing, dose, and disease context, MEK inhibition can attenuate excessive inflammation but may also interfere with protective host defense mechanisms. This duality highlights the context-dependent role of MEK/ERK signaling in infection and inflammation. In this review, I summarize current knowledge on the integration of MEK/ERK signaling into TLR-mediated innate immune responses and discuss the immunological consequences of MEK inhibition in infectious and inflammatory settings. By synthesizing mechanistic and translational studies, I aim to provide a framework for understanding MEK inhibitors as immune modulators rather than as broadly acting anti-inflammatory agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like ReceptorsInflammationProtein Kinase InhibitorsSignal TransductionInfectionsMitogen-Activated Protein Kinase KinasesHumansAnimalsImmunity, InnateMAP Kinase Signaling System

Stichwörter der Autor:innen

MEK inhibitorsMEK/ERK signalingToll-like receptorshost-directed therapyimmune modulationinfection and inflammationinnate immunity

Substanzen

Toll-Like ReceptorsProtein Kinase InhibitorsMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Institute of Immunology, University and University Hospital of Tübingen, 72076 Tübingen, Germany.

ORCID-Profile: Oliver Planz

Förderung

  • Federal Ministry of Education and Research
  • Federal Ministry for Research, Technology and Space

Zitieren

APA

Planz, O. (2026). MEK Inhibitors and Toll-like Receptor Signaling: Implications for Infection and Inflammation. International Journal of Molecular Sciences, 27(13), 5666. https://doi.org/10.3390/ijms27135666

Vancouver

Planz O. MEK Inhibitors and Toll-like Receptor Signaling: Implications for Infection and Inflammation. International Journal of Molecular Sciences. 2026;27(13):5666. doi:10.3390/ijms27135666

BibTeX
@article{Planz2026,
  author = {Planz, Oliver},
  title = {MEK Inhibitors and Toll-like Receptor Signaling: Implications for Infection and Inflammation},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {13},
  pages = {5666},
  doi = {10.3390/ijms27135666}
}
Kostenlos starten →